Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders

Trends in Pharmacological Sciences

Volumn 34, Issue 8, 2013, Pages 445-457

  Buttmann, Mathias ^a   Kaveri, Srini ^b   Hartung, Hans Peter ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b INSERM   (France)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

clinical trials; Guillain Barr syndrome; immunoglobulins; multiple sclerosis; neuromyelitis optica; polyradiculoneuropathy

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; DEMYELINATING DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LOADING DRUG DOSE; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PLASMAPHERESIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; TREATMENT DURATION;

CLINICAL TRIALS; GUILLAIN-BARRÉ SYNDROME; IMMUNOGLOBULINS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; POLYRADICULONEUROPATHY;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CLONE CELLS; DEMYELINATING DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN G; POLYNEUROPATHIES;

EID: 84881164768     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.05.009Review     Document Type: Review

References (204)

1. U. Rothfelder [Therapy of multiple sclerosis with immunoglobulin G] MMW Munch. Med. Wochenschr. 124 1982 74 78
2. M. Vermeulen Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy J. Neurol. Sci. 70 1985 317 326
3. M. Radosevich, and T. Burnouf Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance Vox Sang. 98 2010 12 28
4. M. Spycher In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations Vox Sang. 97 2009 348 354
5. P. Sastre Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities Vaccine 23 2004 435 443
6. R. Blasczyk Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations Lancet 341 1993 789 790
7. E.W. Gelfand Differences between IGIV products: impact on clinical outcome Int. Immunopharmacol. 6 2006 592 599
8. F. Nimmerjahn, and J.V. Ravetch Anti-inflammatory actions of intravenous immunoglobulin Annu. Rev. Immunol. 26 2008 513 533
9. I. Schwab, and F. Nimmerjahn Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13 2013 176 189
10. H.C. Lehmann, and H.P. Hartung Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies J. Neuroimmunol. 231 2011 61 69
11. R. Liblau Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies J. Clin. Immunol. 11 1991 128 131
12. B. Buchwald Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome Ann. Neurol. 51 2002 673 680
13. N. Li Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases J. Clin. Invest. 115 2005 3440 3450
14. S.V. Kaveri Intravenous immunoglobulin: exploiting the potential of natural antibodies Autoimmun. Rev. 11 2012 792 794
15. B. Buchwald Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study Ann. Neurol. 44 1998 913 922
16. B. Buchwald Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome Ann. N. Y. Acad. Sci. 841 1998 659 669
17. B.C. Jacobs Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding Brain 126 2003 2220 2234
18. U. Malik Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen Ann. Neurol. 39 1996 136 139
19. N. Yuki, and F. Miyagi Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies J. Neurol. Sci. 139 1996 160 162
20. G. Zhang Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies Brain 127 2004 1085 1100
21. W. Peng Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1 Immunol. Lett. 143 2012 146 151
22. S. Kusunoki, and K. Kaida Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders J. Neurochem. 116 2011 828 832
23. N. Yuki IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy J. Neurol. Neurosurg. Psychiatry 82 2011 87 91
24. S. Piepers IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN J. Neuroimmunol. 229 2010 256 262
25. M.S. Maddur Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations J. Clin. Immunol. 33 Suppl. 1 2013 S62 S66
26. A. Tournadre Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins Cytokine 46 2009 297 301
27. M.S. Maddur Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin J. Allergy Clin. Immunol. 127 2011 823 830
28. J. Kwekkeboom Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies Adv. Exp. Med. Biol. 750 2012 133 144
29. J. Bayry Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease J. Rheumatol. 39 2012 450 451
30. N. Costa Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells J. Clin. Immunol. 33 2013 349 360
31. L.P. Cousens Tregitope update: mechanism of action parallels IVIg Autoimmun. Rev. 12 2013 436 443
32. A. Kessel Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function J. Immunol. 179 2007 5571 5575
33. A. Mouzaki Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis Blood 100 2002 1774 1779
34. O. Graphou Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions Am. J. Reprod. Immunol. 49 2003 21 29
35. H2 pathway Nature 475 2011 110 113
36. P. Trepanier, and R. Bazin Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation Blood 120 2012 2769 2770
37. A.K. Mausberg Recovery of the T-cell repertoire in CIDP by IV immunoglobulins Neurology 80 2013 296 303
38. L. Padet, and R. Bazin IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators Immunol. Lett. 150 2013 54 60
39. S. Kaveri Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use J. Clin. Invest. 97 1996 865 869
40. J.J. Marchalonis Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain Proc. Natl. Acad. Sci. U.S.A. 89 1992 3325 3329
41. L. Padet Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells? Clin. Exp. Immunol. 166 2011 352 360
42. O. Aktas Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis J. Neuroimmunol. 114 2001 160 167
43. S. Othy Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis J. Immunol. 190 2013 4535 4541
44. 2-Integrin- intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro J. Cell. Physiol. 227 2012 3857 3875
45. A. Creange Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies J. Neuroimmunol. 135 2003 91 95
46. M.K. Sharief IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome Neurology 52 1999 1833 1838
47. S. Reuben Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barré syndrome Neurol. India 51 2003 487 489
48. A. Rissmann Increased blood plasma concentrations of TGF-β1 and TGF-β2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases Pediatr. Allergy Immunol. 20 2009 261 265
49. D. Reinhold Increased blood plasma concentrations of TGF-β isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis J. Neuroimmunol. 152 2004 191 194
50. M. Svenson Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations Blood 91 1998 2054 2061
51. B. Tackenberg Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy J. Clin. Immunol. 30 Suppl. 1 2010 S65 S69
52. S. Bick Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action? J. Neuroimmunol. 256 2013 84 90
53. 2+-dependent signal transduction through Fc gamma receptors in B lymphocytes Scand. J. Immunol. 40 1994 37 42
54. A. Kessel IVIg attenuates TLR-9 activation in B cells from SLE patients J. Clin. Immunol. 31 2011 30 38
55. M. Toyoda Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells Am. J. Transplant. 3 2003 156 166
56. N.K. Prasad Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway J. Immunol. 161 1998 3781 3790
57. I. Mori Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome PLoS ONE 3 2008 e2109
58. J. Bayry Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin Blood 101 2003 758 765
59. J. Bayry Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus Arthritis Rheum. 48 2003 3497 3502
60. S. Othy Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation J. Autoimmun. 39 2012 168 172
61. E. Aubin Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation Blood 115 2010 1727 1734
62. A.R. Crow New insight into the mechanism of action of IVIg: the role of dendritic cells J. Thromb. Haemost. 7 Suppl. 1 2009 245 248
63. J.E. Ruiz Effect of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion J. Reprod. Immunol. 31 1996 125 141
64. C. Jacobi Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity Clin. Immunol. 133 2009 393 401
65. - natural killer cells in multifocal motor neuropathy Eur. Neurol. 53 2005 64 67
66. Y. Ito Effect of intravenous immunoglobulin G on the TNFα-mediated hepatic microvascular inflammatory response Shock 11 1999 291 295
67. C.M. Radder Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells Clin. Exp. Immunol. 137 2004 216 222
68. J.S. Yoon Effects of intravenous immunoglobulin and methylprednisolone on human umbilical vein endothelial cells in vitro Immunobiology 211 2006 351 357
69. C. Xu Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases Am. J. Pathol. 153 1998 1257 1266
70. 2+ mobilization and von Willebrand factor secretion, and increases nitric oxide release in human endothelial cells Thromb. Haemost. 90 2003 1046 1053
71. 2+ movements and nitric oxide production in endothelial cells J. Biol. Chem. 271 1996 26473 26476
72. T. Ichiyama An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary arteries in vitro Inflamm. Res. 53 2004 253 256
73. P.A. van Doorn Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome Lancet Neurol. 7 2008 939 950
74. Y.A. Rajabally, and A. Uncini Outcome and its predictors in Guillain-Barré syndrome J. Neurol. Neurosurg. Psychiatry 83 2012 711 718
75. N. Yuki, and H.P. Hartung Guillain-Barré syndrome N. Engl. J. Med. 366 2012 2294 2304
76. A. Uncini A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies Exp. Neurol. 235 2012 513 516
77. H.C. Lehmann Recent developments and future directions in Guillain-Barré syndrome J. Peripher. Nerv. Syst. 17 Suppl. 3 2012 57 70
78. G. Meyer zu Horste From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve Nat. Clin. Pract. Neurol. 3 2007 198 211
79. N. Yuki Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome Proc. Natl. Acad. Sci. U.S.A. 101 2004 11404 11409
80. R.A. Hughes, and P.A. van Doorn Corticosteroids for Guillain-Barré syndrome Cochrane Database Syst. Rev. 8 2012 CD001446
81. R.H. King Effects of glucocorticoids on experimental allergic neuritis Exp. Neurol. 87 1985 9 19
82. P.M. Watts High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat Exp. Neurol. 103 1989 101 104
83. J.C. Raphael Plasma exchange for Guillain-Barré syndrome Cochrane Database Syst. Rev. 7 2012 CD001798
84. I. Cortese Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 76 2011 294 300
85. H.C. Lehmann Plasma exchange in immune-mediated neuropathies Curr. Opin. Neurol. 21 2008 547 554
86. M. Ceccarelli [Initial experiences in the use of intravenous immunoglobulins in Guillain-Barré-Strohl syndrome] Pediatr. Med. Chir. 9 1987 719 721
87. G. Mauro [A case of Guillain-Barré syndrome treated with intravenous high doses of immunoglobulins] Rev. Neurol. 145 1989 731 732
88. R.P. Kleyweg Treatment of Guillain-Barré syndrome with high-dose gammaglobulin Neurology 38 1988 1639 1641
89. V. Bril Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome Neurology 46 1996 100 103
90. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome Lancet 349 1997 225 230
91. F.G. van der Meche A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome N. Engl. J. Med. 326 1992 1123 1129
92. H.C. Diener A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome Eur. Neurol. 46 2001 107 109
93. T. Hosokawa Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report Ther. Apher. 2 1998 288 291
94. K. Nomura A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome Neurol. Ther. 18 2001 69 81
95. R.A. Hughes Intravenous immunoglobulin for Guillain-Barré syndrome Cochrane Database Syst. Rev. 7 2012 CD002063
96. P. Imbach High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood Lancet 1 1981 1228 1231
97. H.S. Patwa Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 78 2012 1009 1015
98. J.C. Raphael Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days J. Neurol. Neurosurg. Psychiatry 71 2001 235 238
99. L.H. Visser Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features Brain 118 1995 841 847
100. N. Yuki Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside Ann. Neurol. 47 2000 314 321
101. B.C. Jacobs Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome Ann. Neurol. 40 1996 181 187
102. M.A. El-Bayoumi Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study Crit. Care 15 2011 R164
103. K. Kuitwaard Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome Ann. Neurol. 66 2009 597 603
104. P.A. van Doorn IVIG treatment and prognosis in Guillain-Barré syndrome J. Clin. Immunol. 30 Suppl. 1 2010 S74 S78
105. R.S. Laughlin Incidence and prevalence of CIDP and the association of diabetes mellitus Neurology 73 2009 39 45
106. H. Köller Chronic inflammatory demyelinating polyneuropathy N. Engl. J. Med. 352 2005 1343 1356
107. M.C. Dalakas Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies J. Peripher. Nerv. Syst. 17 Suppl. 2 2012 34 39
108. D.R. Cornblath Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force Neurology 41 1991 617 618
109. M.B. Bromberg Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy Muscle Nerve 43 2011 780 794
110. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision J. Peripher. Nerv. Syst. 15 2010 1 9
111. R.A. Hughes, and M.M. Mehndiratta Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy Cochrane Database Syst. Rev. 8 2012 CD002062
112. E. Nobile-Orazio Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial Lancet Neurol. 11 2012 493 502
113. F. Eftimov Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment Neurology 78 2012 1079 1084
114. M. Mahdi-Rogers Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Cochrane Database Syst. Rev. 11 2010 CD003280
115. M.M. Mehndiratta, and R.A. Hughes Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Cochrane Database Syst. Rev. 9 2012 CD003906
116. J.R. Mendell Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy Neurology 56 2001 445 449
117. M. Vermeulen Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study J. Neurol. Neurosurg. Psychiatry 56 1993 36 39
118. P.A. van Doorn High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study Neurology 40 1990 209 212
119. N. Thompson A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy J. Neurol. 243 1996 280 285
120. A.F. Hahn Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study Brain 119 Pt 4 1996 1067 1077
121. I.N. Van Schaik Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy Cochrane Database Syst. Rev. 2 2002 CD001797
122. P.J. Dyck A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy Ann. Neurol. 36 1994 838 845
123. R.A. Hughes Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial Lancet Neurol. 7 2008 136 144
124. R. Hughes Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy Ann. Neurol. 50 2001 195 201
125. N. Latov Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy Arch. Neurol. 67 2010 802 807
126. P.D. Donofrio Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy Arch. Neurol. 67 2010 1082 1088
127. V. Bril Electrophysiologic correlations with clinical outcomes in CIDP Muscle Nerve 42 2010 492 497
128. V. Bril Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV Muscle Nerve 39 2009 448 455
129. I.S. Merkies Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study Neurology 72 2009 1337 1344
130. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society J. Peripher. Nerv. Syst. 11 2006 9 19
131. L.H. Markvardsen Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy Eur. J. Neurol. 20 2013 836 842
132. D. Cocito The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin J. Peripher. Nerv. Syst. 16 2011 150 152
133. D.H. Lee Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy Muscle Nerve 37 2008 406 409
134. H. Köller Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies J. Neurol. 253 2006 1505 1506
135. M. Iijima Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP Neurology 73 2009 1348 1352
136. G.J. Parry, and S. Clarke Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease Muscle Nerve 11 1988 103 107
137. A.S. Pakiam, and G.J. Parry Multifocal motor neuropathy without overt conduction block Muscle Nerve 21 1998 243 245
138. J.T. Van Asseldonk Axon loss is an important determinant of weakness in multifocal motor neuropathy J. Neurol. Neurosurg. Psychiatry 77 2006 743 747
139. S.A. Muley, and G.J. Parry Multifocal motor neuropathy J. Clin. Neurosci. 19 2012 1201 1209
140. R.N. Auer Neuropathy with onion bulb formations and pure motor manifestations Can. J. Neurol. Sci. 16 1989 194 197
141. R. Kaji Pathological findings at the site of conduction block in multifocal motor neuropathy Ann. Neurol. 33 1993 152 158
142. R. Kaji Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy Muscle Nerve 17 1994 108 110
143. B.V. Taylor Multifocal motor neuropathy: pathologic alterations at the site of conduction block J. Neuropathol. Exp. Neurol. 63 2004 129 137
144. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision J. Peripher. Nerv. Syst. 15 2010 295 301
145. L.H. Van den Berg Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study J. Neurol. Neurosurg. Psychiatry 59 1995 248 252
146. J.P. Azulay Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study Neurology 44 1994 429 432
147. J.M. Leger Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study Brain 124 2001 145 153
148. P. Federico Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study Neurology 55 2000 1256 1262
149. I.N. van Schaik Intravenous immunoglobulin for multifocal motor neuropathy Cochrane Database Syst. Rev. 2 2005 CD004429
150. M. Sonoo [Motor-dominant neuropathy with multifocal conduction block] Rinsho Shinkeigaku 30 1990 1214 1220
151. A.G. Kermode Intravenous immunoglobulin for multifocal motor neuropathy Lancet 340 1992 920 921
152. T. Harbo Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial Eur. J. Neurol. 16 2009 631 638
153. F. Eftimov Subcutaneous immunoglobulin therapy for multifocal motor neuropathy J. Peripher. Nerv. Syst. 14 2009 93 100
154. P. Dacci Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report Neurol. Sci. 31 2010 829 831
155. T. Harbo Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy Neurology 75 2010 1377 1380
156. S.A. Misbah A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study J. Peripher. Nerv. Syst. 16 2011 92 97
157. M. Donaghy Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin J. Neurol. Neurosurg. Psychiatry 57 1994 778 783
158. M. Carpo Deterioration of multifocal motor neuropathy after plasma exchange Neurology 50 1998 1480 1482
159. H.C. Lehmann The clinical value of therapeutic plasma exchange in multifocal motor neuropathy J. Neurol. Sci. 271 2008 34 39
160. T. Umapathi Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy Cochrane Database Syst. Rev. 4 2012 CD003217
161. S. Piepers Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain 130 2007 2004 2010
162. C.H. Polman Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Ann. Neurol. 69 2011 292 302
163. J.J. Marriott, and P.W. O'Connor Definitions of breakthrough disease and second-line agents Neurol. Clin. 29 2011 411 422
164. J. Ingwersen Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy Clin. Immunol. 142 2012 15 24
165. M. Buttmann Treating multiple sclerosis with monoclonal antibodies: a 2010 update Expert Rev. Neurother. 10 2010 791 809
166. H.P. Hartung Principles of a new treatment algorithm in multiple sclerosis Expert Rev. Neurother. 11 2011 351 362
167. A. Deiss Treating multiple sclerosis with monoclonal antibodies: a 2013 update Expert Rev. Neurother. 13 2013 313 335
168. J.J. Marriott Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
169. E. Lu Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review Neurology 79 2012 1130 1135
170. E. Schuller, and A. Govaerts First results of immunotherapy with immunoglobulin G in multiple sclerosis patients Eur. Neurol. 22 1983 205 212
171. W. Soukop, and H. Tschabitscher [Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy] Wien. Med. Wochenschr. 136 1986 477 480
172. J. Yan High-dose intravenous immunoglobulin for multiple sclerosis Lancet 336 1990 692
173. A. Achiron Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis Arch. Neurol. 49 1992 1233 1236
174. O. Gray Intravenous immunoglobulins for multiple sclerosis Cochrane Database Syst. Rev. 4 2003 CD002936
175. F. Fazekas Intravenous immunoglobulin in MS: promise or failure? J. Neurol. Sci. 259 2007 61 66
176. M. Lewanska No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment Eur. J. Neurol. 9 2002 565 572
177. A. Achiron Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses Neurology 50 1998 398 402
178. F. Fazekas Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis Lancet 349 1997 589 593
179. M. Teksam Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report Neuroradiology 42 2000 885 889
180. P.S. Sorensen Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis Neurology 50 1998 1273 1281
181. F. Fazekas Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial Neurology 71 2008 265 271
182. W.K. Engel Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial Neurology 73 2009 1077 author reply 1077-1078
183. O.A. Khan Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial Neurology 72 2009 2134 author reply 2134-2135
184. A. Achiron Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial Arch. Neurol. 61 2004 1515 1520
185. A. Achiron Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis J. Neurol. 251 2004 1133 1137
186. J. Haas, and O.R. Hommes A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis Mult. Scler. 13 2007 900 908
187. K. Hellwig Immunomodulation and postpartum relapses in patients with multiple sclerosis Ther. Adv. Neurol. Disord. 2 2009 7 11
188. A. Tselis Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin Eur. J. Neurol. 15 2008 1163 1167
189. P.S. Sorensen IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS Neurology 63 2004 2028 2033
190. H.G. Roed A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis Neurology 64 2005 804 810
191. J.H. Noseworthy A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis Neurology 56 2001 1514 1522
192. J.H. Noseworthy IV immunoglobulin does not reverse established weakness in MS Neurology 55 2000 1135 1143
193. O.R. Hommes Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial Lancet 364 2004 1149 1156
194. D. Pöhlau Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study Mult. Scler. 13 2007 1107 1117
195. M.C. Papadopoulos, and A.S. Verkman Aquaporin 4 and neuromyelitis optica Lancet Neurol. 11 2012 535 544
196. D. Sato Treatment of neuromyelitis optica: an evidence based review Arq. Neuropsiquiatr. 70 2012 59 66
197. B.C. Kieseier Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses JAMA Neurol. 70 2013 390 393
198. M.J. Magraner The effect of intravenous immunoglobulin on neuromyelitis optica Neurologia 28 2013 65 72
199. K. Okada Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica Intern. Med. 46 2007 1671 1672
200. J. Bakker, and L. Metz Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG) Can. J. Neurol. Sci. 31 2004 265 267
201. D.B. Bichuetti Treatment of neuromyelitis optica with intravenous immunoglobulin: report of 8 patients Neurology 78 2012 (Meeting Abstracts 1), P04.141
202. M. Houtchens Neuromyelitis optica in pregnancy: treatment with intravenous immunoglobulin Abstracts of the 28th Congress of the European
203. Y. Nakano [Senile-onset recurrent myelitis with anti-aquaporin-4 antibody] Brain Nerve 61 2009 601 604
204. Y. Ii Reversible stenosis of large cerebral arteries in a patient with combined Sjogren's syndrome and neuromyelitis optica spectrum disorder Rheumatol. Int. 28 2008 1277 1280